Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2018 | Results from CAR T-cell bb2121 first-in-human trial for R/R MM

The anti-BCMA CAR T-cell therapy bb2121 looks extremely promising in multiple myeloma (MM). Here, Noopur Raje, MD, of Massachusetts General Hospital Cancer Center, Boston, MA, discusses the results of CRB-401 (NCT02658929), a first-in-human trial of bb2121 in relapsed/refractory MM, which were presented at the American Society of Oncology (ASCO) 2018 Annual Meeting in Chicago, IL. Prof. Raje also highlights avenues for further study and the key questions that remain to be answered.